AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amphastar Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$26.14+0.27 (+1.04%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- 15.4
- Dividend yield
- –
Amphastar Pharmaceuticals, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Finished Pharmaceutical Products Segment | $183.90M | $171.17M | – | $191.84M | $174.41M | $170.53M | – | $191.21M | $182.39M | $171.84M | $175.03M | $176.37M | 100.0% | +5.4% |
| Active Pharmaceutical Ingredient Segment | – | – | – | – | – | – | – | $1.46M | $3.54M | $1.69M | $3.07M | $4.19M | – | – |
| Pharmaceutical products segment | – | $171.17M | – | – | – | $170.53M | – | – | – | $171.84M | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | – | – | $183.11M | $191.84M | $174.41M | $170.53M | $186.98M | $188.82M | $179.39M | $157.63M | $155.65M | $151.86M | – | – |
| Other | – | – | – | – | – | – | – | $2.40M | $3.01M | $14.21M | $22.46M | $28.70M | – | – |
| Lidocaine | – | – | – | – | – | – | – | – | – | $12.77M | – | – | – | – |
| Other product revenues, net | – | – | – | – | – | – | – | – | – | $29.15M | – | – | – | – |
| Phytonadione | – | – | – | – | – | – | – | – | – | $9.97M | – | – | – | – |
| Enoxaparin | – | – | – | – | – | – | – | – | – | $7.10M | – | – | – | – |
| Glucagon | – | – | – | – | – | – | – | – | – | $28.54M | – | – | – | – |
| Naloxone | – | – | – | – | – | – | – | – | – | $4.29M | – | – | – | – |
| Primatene MIST | – | – | – | – | – | – | – | – | – | $24.17M | – | – | – | – |
| Epinephrine | – | – | – | – | – | – | – | – | – | $26.11M | – | – | – | – |
| API | – | – | – | – | – | – | – | – | – | $1.69M | – | – | – | – |
| BAQSIMI | – | – | – | – | – | – | – | – | – | $13.84M | – | – | – | – |
| BAQSIMI NEB | – | – | – | – | – | – | – | – | – | $14.21M | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $172.34M | $159.04M | $171.55M | $180.28M | $167.00M | $162.59M | $175.09M | $186.51M | $176.42M | $169.66M | $175.28M | $178.06M | 93.7% | +3.2% |
| France | $7.00M | $9.65M | $10.63M | $9.68M | $7.11M | $7.86M | $9.24M | $4.52M | $4.41M | $1.78M | $459.00K | $1.67M | 3.8% | -1.6% |
| China | $4.56M | $2.48M | $925.00K | $1.88M | $299.00K | $81.00K | $2.19M | $178.00K | $1.56M | $403.00K | $2.36M | $833.00K | 2.5% | +1425.1% |
From the segment and revenue-disaggregation notes of Amphastar Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.